A Value-Based Medicine cost-utility analysis of genetic testing for neovascular macular degeneration

Table 3 Fellow eye conversion to neovascular AMD in the MARINA/ANCHOR trials, Barbazetto et al. [39]

By end of year	A	B = 46.4 % + (A × 53.5 %)
By end of year	Cumulative, incremental, conversion rate of the 53.6 % unilateral, neovascular AMD cases at baseline (%)	Bilateral involvement (%)
Baseline	0.0	46.4
Year 1	21.2	57.7
Year 2	38.0	66.8
Year 3	49.8	73.1
Year 4	59.5	78.3
Year 5	67.2	82.4
Year 6	73.4	85.7
Year 7	78.5	88.5
Year 8	82.6	90.6
Year 9	85.9	92.4
Year 10	88.6	93.9
Year 11	90.7	95.0
Year 12	92.5	96.0
Final	92.5	96.0

Baseline, year 1 and year 2 prevalences are based upon primary data [39], while years 3–12 are based upon the average incidence of conversion to neovascular during years 1 and 2, using a last observation carried forward (LOCF) methodology with Markov modeling
AMD age-related macular degeneration

ISSN: 2056-9920